title: Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
abstract: Here, we evaluated the in vitro anti-HIV-1 activity of the experimental CCR5 inhibitor VCH-286 as a single agent or in combination with various classes of HIV-1 inhibitors. Although VCH-286 used alone had highly inhibitory activity, paired combinations with different drug classes led to synergistic or additive interactions. However, combinations with other CCR5 inhibitors led to effects ranging from synergy to antagonism. We suggest that caution should be exercised when combining CCR5 inhibitors in vivo.
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada Department de Microbiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, Canada.
authors.forename: Odalis
authors.initials: O
authors.lastname: Asin-Milan
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Sylla
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Far
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Belanger-Jasmin
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Alpha
authors.initials: A
authors.lastname: Haidara
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Julie
authors.initials: J
authors.lastname: Blackburn
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
authors.forename: Annie
authors.initials: A
authors.lastname: Chamberland
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada Department de Microbiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, Canada Laboratoire de Santé Publique du Québec/Institut National de Santé Publique du Québec, Montréal, Canada c.tremblay@umontreal.ca.
authors.forename: Cécile L
authors.initials: CL
authors.lastname: Tremblay
mesh_terms: D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000378:metabolism / Q000494:pharmacology*; D004336:Drug Antagonism; D004338:Drug Combinations; D004357:Drug Synergism; D015870:Gene Expression; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000821:virology; D000077592:Maraviroc; D008826:Microbial Sensitivity Tests; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology*; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism*; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D013141:Spiro Compounds / Q000378:metabolism / Q000494:pharmacology*; D014230:Triazoles / Q000378:metabolism / Q000494:pharmacology*; D014326:Tropanes / Q000378:metabolism / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; C584933:CCR5 protein, human; D003510:Cyclohexanes; D004338:Drug Combinations; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; D018894:Reverse Transcriptase Inhibitors; D013141:Spiro Compounds; D014230:Triazoles; D014326:Tropanes; C000599188:VCH-286; D000077592:Maraviroc; C486781:vicriviroc